Loading clinical trials...
Loading clinical trials...
Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy: a Randomized, Double-blind, Placebo-controlled Trial.
Conditions
Interventions
Melatonin 20 MG Oral Capsule
Placebo oral capsule
Start Date
January 1, 2016
Primary Completion Date
January 1, 2017
Completion Date
January 1, 2017
Last Updated
July 2, 2017
NCT07360600
NCT06793397
NCT07478393
NCT04123314
NCT06906939
NCT05851898
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions